Legend Biotech (LEGN) Net Income towards Common Stockholders (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Net Income towards Common Stockholders data on file, last reported at $2.5 million in Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders fell 95.76% year-over-year to $2.5 million; the TTM figure through Dec 2025 stood at -$261.1 million (up 30.05% YoY), while the FY2025 annual figure was $33.1 million, down 82.47% from the prior year.
• Net Income towards Common Stockholders grew to $2.5 million in Q4 2025, from -$38.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $59.0 million in Q4 2024 and bottomed at -$199.1 million in Q2 2023.
• A 5-year average of -$88.0 million and a median of -$96.2 million in 2021 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 35570.18% — and 2024, when it surged 40840.79%.
• Year by year, Net Income towards Common Stockholders stood at -$88.3 million in 2021, then plunged by 53.82% to -$135.9 million in 2022, then soared by 99.89% to -$144818.0 in 2023, then surged by 40840.79% to $59.0 million in 2024, then slumped by 95.76% to $2.5 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at $2.5 million (Q4 2025), -$38.5 million (Q3 2025), and -$124.2 million (Q2 2025), per Business Quant data.

Peer Comparison